Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Reviva Pharmaceuticals Holdings, Inc. RVPH

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug... see more

Recent & Breaking News (NDAQ:RVPH)

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

GlobeNewswire 6 days ago

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

GlobeNewswire 9 days ago

Reviva Announces Proposed Public Offering

GlobeNewswire 9 days ago

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

GlobeNewswire 10 days ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire November 14, 2024

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

GlobeNewswire November 12, 2024

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

GlobeNewswire November 6, 2024

Reviva to Participate in the UBS Global Healthcare Conference

GlobeNewswire October 31, 2024

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 8, 2024

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire October 2, 2024

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

GlobeNewswire September 26, 2024

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

GlobeNewswire September 9, 2024

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

GlobeNewswire August 27, 2024

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire August 21, 2024

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire August 14, 2024

Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire August 6, 2024

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

GlobeNewswire July 9, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

Newsfile June 3, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

Accesswire June 1, 2024